瑋俊生物科技(00660.HK):萬波辭任獨立非執行董事
格隆匯6月5日丨瑋俊生物科技(00660.HK)公告,均自2025年6月5日起生效:(1)萬波先生已辭任獨立非執行董事。於萬先生辭任後,彼亦不再擔任公司提名委員會主席,以及審覈委員會及薪酬委員會各自的成員;(2)何濤先生已辭任獨立非執行董事。於何先生辭任後,彼亦不再擔任公司薪酬委員會主席,以及審覈委員會及提名委員會各自的成員;(3)許慧齡女士已獲委任爲獨立非執行董事,以及公司審覈委員會,薪酬委員會及提名委員會各自的成員;(4)王子牛先生已獲委任爲獨立非執行董事,以及公司薪酬委員會主席,及審覈委員會及提名委員會各自的成員;及(5)林家俊先生已獲委任爲公司提名委員會主席。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.